TITLE

Venlafaxine and paroxetine in treatment-resistant depression

AUTHOR(S)
Poirier, M.-F.; Boyer, P.
PUB. DATE
July 1999
SOURCE
British Journal of Psychiatry;Jul99, Vol. 175, p12
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background About one-third of patients fail to respond to initial antidepressant therapy, which suggests a need for more effective drugs. Aims To compare the efficacy and safety of venlafaxine and paroxetine in 122 patients with non-chronic treatment-resistant depression. Method In-patients or out-patients satisfying DSM-III-R criteria for major depression in evolution for less than eight months, having a baseline HAM-D score ⩾ 18 and a HAM-D Item 3s core < 3 were eligible. Patients were required to have a history of resistance to two previous antidepressant treatments and a CGI improvement score of 3 at the beginning of treatment. Doses were adjusted to 200-300 mg/day for venlafaxine and 30-40 mg/day for paroxetine. Results For the observed-case analysis, the response rate was 51.9% for venlafaxine and 32.7% for paroxetine (P=0.044), and a remission was achieved in 42.3% of venlafaxine-treated and 20.0% of paroxetine-treated patients (P=0.01). The incidence of adverse effects was comparable between treatment groups. Conclusions Venlafaxine showed some evidence of superiority to paroxetine in this difficult-to-treat patient population.
ACCESSION #
25163976

 

Related Articles

  • Spotlight on escitalopram in the management of major depressive disorder. Murdoch, David; Keam, Susan J. // CNS Drugs;2006, Vol. 20 Issue 2, p167 

    Escitalopram (Cipralex), Lexapro), the active S-enantiomer of the racemic SSRI citalopram (RS-citalopram), is a highly selective inhibitor of the serotonin transporter protein. It possesses a rapid onset of antidepressant activity, and is an effective and generally well tolerated treatment for...

  • Early-Stage Psychotherapy Produces Elevated Frontal White Matter Integrity in Adult Major Depressive Disorder. Wang, Tao; Huang, Xiaolan; Huang, Peiyu; Li, Dan; Lv, Fajin; Zhang, Yong; Zhou, Linke; Yang, Deyu; Xie, Peng // PLoS ONE;Apr2013, Vol. 8 Issue 4, p1 

    Background: Psychotherapy has demonstrated comparable efficacy to antidepressant medication in the treatment of major depressive disorder. Metabolic alterations in the MDD state and in response to treatment have been detected by functional imaging methods, but the underlying white matter...

  • Retooling Multiple Levels to Improve Primary Care Depression Treatment. Rost, Kathryn // JGIM: Journal of General Internal Medicine;Sep2001, Vol. 16 Issue 9, p641 

    Comments on the key requirements of treating mental depression. Recognition of the condition's impact on multiple levels of an individual's life; Ways to improve primary care depression treatment; Complexity of clinical and organizational problems.

  • Defining, recognizing and managing depression. House, Allan // Practical Neurology;Aug2003, Vol. 3 Issue 4, p196 

    Focuses on mental depression. Recognition of depressive disorders; Management of depressive disorders; Role of psychological therapies in treating the disorders.

  • Effective Treatment for Depression: St. John's Wort.  // Annals of the American Psychotherapy Association;Winter2008, Vol. 11 Issue 4, p7 

    The article presents information on a study which examined the therapeutic use of St. John's wort for treating mental depression. Participants of the study were asked to rate the severity of their depression after taking various treatments, using the Hamilton Rating Scale for Depression. The...

  • Comparison of pharmacological treatment response between situational and non-situational depressions. Garvey, Michael J.; Schaffer, Charles B.; Tuason, V.B.; Garvey, M J; Schaffer, C B // British Journal of Psychiatry;Oct84, Vol. 145, p363 

    Fifty-one patients with a primary major depressive disorder preceded by a stressful environmental event were compared for their response to pharmacological treatment with 75 depressives who experienced no stressful life event before illness episodes. There was no difference between the groups in...

  • Biochemical aspects of therapy-resistant depression. Leonard, B. E. // British Journal of Psychiatry;Apr88, Vol. 152, p453 

    Despite the relatively high incidence of therapy-resistant depression, there is little clinical evidence to suggest that there are significant biochemical differences between therapy-resistant and therapy-responsive patients. A major problem for investigators is the lack of an internationally...

  • When antidepressants don't work. Cowen, Philip // Pulse;2/9/2004, Vol. 64 Issue 6, p45 

    Explains the reasons on the ineffectiveness of antidepressants and how to solve the problem. Administration of the appropriate dosage; Recognition of dose-response curves; Decision of switching to an alternative drug; Consideration of using monoamine oxidase inhibitors; Augmentation strategies.

  • Science News recently reported a study that collected data on more than 2,500 patients prescribed any of four antidepressants: two SSRIs and two older drugs.  // Antidepressants & Suicide: When Treatment Kills;2007, p84 

    The article reports about the results of the study done on the effects of anti-depressants to 2,500 patients. Two older drugs and two selective serotonin reuptake inhibitors including fluoxetine and paroxetine were used in the experiment. Results showed that both attempted and completed suicides...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics